The recent announcement that NHS England will be abolished presents significant changes for pharmaceutical companies commercialising their therapies in the UK. After all, commissioning specialised services – the process of planning, agreeing, purchasing and monitoring health and care services to meet the needs of the population, ensuring the best possible health outcomes – has traditionally been a core role of NHS England.
For pharmaceutical companies with a pipeline of new treatments, the transition away from NHS England will pose a unique challenge. With Integrated Care Boards (ICBs) now taking on this responsibility, there will be increased complexity and potentially variability in how new technologies will be adopted and embedded in local service pathways. For industry players, this means a heightened need for tailored strategies and a requirement to work closely with ICBs, ensuring timely and effective implementation of new therapies. Companies will need to adapt their approach, ensuring seamless collaboration and efficient market access.
Oncology services have been at the forefront of the shift from central to local commissioning. The absence of a central body responsible for coordinating the implementation of new treatments means that pharmaceutical companies will need to navigate a much broader network of NHS organisations. This could potentially lead to delays in patient access and make it more difficult to develop unified strategies to address product adoption challenges post-HTA approval. Companies will therefore be required to broaden their outreach, working with multiple organisations to ensure smoother transitions from approval to access.
At NeoHealthHub, we have always been a critical access lifeline to our clients. However, these recent announcements now mean that access, fused with up-to-date intelligence about what is happening within each locality, is now more important than ever. We are passionate about helping pharmaceutical, biotech and medical device companies navigate these complexities, providing tailored strategies from development to execution, ensuring the right patients receive the right therapies at the right time.